Resiliva is identified for this website as a product containing resmetirom in stated 80 mg and 100 mg strengths. Product-specific manufacturer and authorization information are Everest Pharmaceuticals Ltd.
Resmetirom is a selective thyroid hormone receptor beta agonist developed as a liver-directed therapy for MASH/NASH with liver fibrosis. Its established reference product is Rezdiffra, manufactured and marketed by Madrigal Pharmaceuticals. FDA approved Rezdiffra in 2024, while the EMA granted conditional authorization in the EU in 2025.
| Attribute | Information |
|---|---|
| Product | Resiliva |
| Generic name | Resmetirom |
| Stated strengths | 80 mg and 100 mg |
| Drug class | THR-β agonist |
| Route | orally |
| Reference medicine | Rezdiffra |
| U.S. reference-product company | Madrigal Pharmaceuticals |
| Resiliva manufacturer | Everest Pharmaceuticals Ltd. |
The 80 mg and 100 mg amounts describe the quantity of resmetirom in each dosage unit. Under current U.S. Rezdiffra labeling, weight determines the recommended daily dose: 80 mg once daily for patients weighing less than 100 kg and 100 mg once daily for patients weighing 100 kg or more.
A generic or alternative branded product should not automatically be called identical to Rezdiffra. The active ingredient may be the same while formulation, excipients, manufacturer, packaging and regulatory authorization differ.
Originator and reference-product history
Resmetirom was originally developed by VIA Pharmaceuticals under a license from F. Hoffmann-La Roche. Madrigal Pharmaceuticals subsequently acquired the relevant rights and obligations in 2011 and continued development of MGL-3196, the compound that became resmetirom.